Deep dive: Pinealon (PEPTIDES.md Section 4.3, Tier 4 — Avoid) — replaces previously lumped mention within Khavinson section with full ~219-line analysis. Discovery: Khavinson group St Petersburg, Glu-Asp-Arg tripeptide as cytogen subset. Proposed Khavinson mechanism (site-directed DNA binding to promoter regions, cell-penetration, transcription factor mimicry, organ-specific gene regulation). Information-theoretic objection as central critique: 3-mer = ~13 bits sequence info vs ~31.5 bits needed for unique site in 3 Gb genome — gap is intrinsic. Three additional convergent biophysics objections: serum peptidase kinetics, absent CPP structural motifs, no ITC/SPR confirmation. Animal evidence covered (Khavinson rodent studies on cognition/ischemia/aging). Human evidence gap (only small unblinded Russian trials). Twitter/social media promotion concern noted honestly. Sourcing concerns (Russian vendors, unverifiable purity). Safety profile (limited Khavinson tox only). Genotype interactions (APOE ε4, DIO2 het, CLOCK CC). Evidence summary table 8 claims. 14 references. Framework alignment: Tier 4 on mechanism implausibility AS CLAIMED + evidence quality grounds. Not claiming biologically inert — door left open for downstream effect via free amino acids or NO-substrate Arg. §4.2 Khavinson reframed as broader methodological critique. GLP-1 cross-ref bumped 4.3 → 4.4. File 734 → 963 lines.

PEPTIDES.md

@@ -53,8 +53,9 @@
 **Tier 4 — Avoid (framework-misaligned or poorly evidenced)**
 
 - 4.1 [Melanotan II](#41-melanotan-ii)
-- 4.2 [Khavinson School Bioregulators — Epitalon, Vesugen, Pinealon and the wider "peptide bioregulator" pharmacopoeia](#42-khavinson-school-bioregulators)
-- 4.3 [Semaglutide / Tirzepatide → cross-reference SUPPLEMENTS.md Section 4.7](#43-glp-1-agonists)
+- 4.2 [Khavinson School Bioregulators — Methodological Overview (Epitalon, Vesugen, and the wider "peptide bioregulator" pharmacopoeia)](#42-khavinson-school-bioregulators)
+- 4.3 [Pinealon (Glu-Asp-Arg / EDR)](#43-pinealon)
+- 4.4 [Semaglutide / Tirzepatide → cross-reference SUPPLEMENTS.md Section 4.7](#44-glp-1-agonists)
 
 ---
 
@@ -694,23 +695,251 @@ Detailed analysis: pending.
 
 ---
 
-## 4.2 Khavinson School Bioregulators (Epitalon, Vesugen, Pinealon, and the wider "peptide bioregulator" pharmacopoeia)
+## 4.2 Khavinson School Bioregulators — Methodological Overview (Epitalon, Vesugen, and the wider "peptide bioregulator" pharmacopoeia)
 
 **Tier:** 4 — Avoid (with caveat that the evidence question is genuinely unresolved)
-**Class:** Short peptides (2-4 amino acids typically) developed by Vladimir Khavinson's group (St Petersburg Institute of Bioregulation and Gerontology, Russia) over ~40 years; claimed to be organ-specific bioregulators (e.g., Epitalon → pineal; Vesugen → vascular; Pinealon → CNS)
+**Class:** Short peptides (2-4 amino acids typically) developed by Vladimir Khavinson's group (St Petersburg Institute of Bioregulation and Gerontology, Russia) over ~40 years; claimed to be organ-specific bioregulators (e.g., Epitalon → pineal; Vesugen → vascular; Pinealon → CNS; Cortagen → cortical; Prostamax → prostate)
 **Status:** Sold extensively as research chemicals; some marketed in Russia and Eastern Europe as supplements
+**Scope of this section:** Methodological and historical critique of the whole peptide-bioregulator programme. For the most prominent individual peptide deep dive, see §4.3 Pinealon. Epitalon (Ala-Glu-Asp-Gly), Vesugen (Lys-Glu-Asp), Cortagen (Ala-Glu-Asp-Pro), and the remainder of the "cytogen" series share the same methodological issues outlined below and are not individually expanded.
 
-**Mechanism summary (claimed):** Tetrapeptide (Epitalon = Ala-Glu-Asp-Gly) said to upregulate telomerase, restore pineal melatonin secretion, normalise circadian rhythm, slow aging. Khavinson group has published claims of lifespan extension in mice, telomere lengthening in human lymphocytes, mortality reduction in elderly cohorts.
+**The two distinct Khavinson series.** The Khavinson programme has two layers:
+- **Cytomedines** — crude polypeptide extracts from animal organs (calf thymus → Thymalin / Vilon; pineal → Epithalamin; prostate → Prostatilen). These are heterogeneous extracts containing many peptides, proteins, and small molecules; framework analysis of any cytomedine is essentially the analysis of an unfractionated tissue extract.
+- **Cytogens** — short synthetic peptides (typically dipeptides, tripeptides, tetrapeptides) intended as "active substance" analogues of the cytomedines. Epitalon, Pinealon, Vesugen, Cortagen all fall here. The cytogen concept is that 2-4 amino-acid sequences carry the "bioregulatory information" of the parent extract — a claim that is mechanistically the core of the controversy.
 
-**Mechanism summary (skeptical reading):** A 4-amino-acid peptide injected subcutaneously will be degraded by serum peptidases within minutes; the proposed mechanism of organ-specific gene regulation by a 4-mer is mechanistically implausible (4-mers have insufficient information content to bind specific transcription factor sites with high affinity); the Khavinson-group literature is poorly replicated outside the originating institute; the "human cohort" mortality data has methodological weaknesses including non-blinded administration and selection bias.
+**Mechanism summary (claimed).** The Khavinson group's central hypothesis (Khavinson 2011 *Neuro Endocrinol Lett*; Khavinson 2014 *Biochemistry Moscow Supplement Series B*) is that short peptides act as **site-specific transcription factor mimetics** — they enter cells, traverse the nuclear envelope, bind specific promoter regions of organ-relevant genes (claimed via direct interaction with the major groove of duplex B-DNA), and thereby regulate organ-specific gene expression. Specific claims include Epitalon upregulating telomerase, restoring pineal melatonin secretion, normalising circadian rhythm, and extending lifespan in mice and (in their cohort studies) reducing mortality in elderly Russian subjects.
 
-**Framework alignment:** The mechanistic claims, if true, would be framework-aligned (melatonin restoration → circadian → mitochondrial; telomerase activation → replicative reserve). The mechanistic plausibility and evidence-quality concerns are large enough to recommend avoidance until independent Western replication appears. **Honest assessment: this is one of the largest evidence-quality gaps in the entire peptide field.** Tier 4 placement reflects the evidence-base failure, not certainty that the compounds are inactive.
+**Mechanism summary (skeptical reading).** Four convergent biophysics objections apply across the whole cytogen series and are spelled out in detail for Pinealon in §4.3 (information theory; serum peptidase half-life; cell penetration; affinity verification). In brief: a 2-4 amino acid peptide has insufficient information content to specify a unique site in a 3 Gb genome; serum peptidase degradation half-life is short (minutes); the proposed cell-penetration and nuclear-import behaviour conflicts with established CPP and nuclear-localisation-signal motif requirements; and the proposed DNA binding affinity has not been confirmed by the standard biophysics methods (ITC, SPR, X-ray crystallography, NMR, cryo-EM).
 
-Detailed analysis: pending.
+**Replication landscape.** The Khavinson-group corpus is large (Khavinson lists ~400 publications on cytogens since 1980) but the corpus is concentrated within the St Petersburg Institute of Bioregulation and Gerontology and a small network of collaborating Russian institutes. Independent replication outside the Khavinson network is thin. Standard PubMed search returns essentially no Western-authored RCT testing any cytogen with adequate blinding, registration, and pre-specified endpoints. The "human cohort" mortality data underpinning Epitalon's longevity claims (Khavinson 2003 *Neuro Endocrinol Lett*) was unblinded, non-randomised in the modern sense, and conducted entirely within the Khavinson institutional network. This is not by itself proof of fabrication — Russian biomedical institutions operated under different methodological norms, particularly during the late Soviet and early post-Soviet period — but it does mean the cytogen evidence base has not survived the standard external replication that grounds Western pharmacology.
+
+**Framework alignment.** The mechanistic claims, *if true*, would be framework-aligned (melatonin restoration → circadian → mitochondrial; telomerase activation → replicative reserve; organ-specific maintenance of pineal, thymic, vascular function). The mechanistic plausibility and evidence-quality concerns are large enough to recommend avoidance until independent Western replication appears. **Honest assessment: this is one of the largest evidence-quality gaps in the entire peptide field.** Tier 4 placement reflects the evidence-base failure and the mechanism implausibility *as claimed*, not certainty that the compounds are biologically inert. It is entirely possible that some cytogens have real effects through mechanisms that are not the site-directed DNA-binding mechanism the Khavinson group proposes — e.g., free-amino-acid pool effects after rapid proteolysis, transient receptor effects analogous to neuropeptide signalling, or nonspecific chaperone-mimetic effects. None of those alternative mechanisms would underwrite the specific claims of organ-targeted gene regulation.
+
+**For the most-discussed individual cytogen (Pinealon), see §4.3.**
 
 ---
 
-## 4.3 Semaglutide / Tirzepatide / GLP-1 Receptor Agonists
+<a id="43-pinealon"></a>
+
+## 4.3 Pinealon (Glu-Asp-Arg / EDR)
+
+> **Tier 4 placement rationale:** Pinealon is placed in Tier 4 on two convergent grounds. First, an evidence-quality failure: there are no large independent Western RCTs, the human evidence base is dominated by small unblinded Russian trials from the originating institute, and the rodent literature is replicated thinly outside the Khavinson network. Second, and more importantly, a mechanism-plausibility failure: the central claim that a tripeptide performs site-directed promoter binding to organ-specific genes is on its face inconsistent with basic information theory, with serum peptidase kinetics, and with the established biophysics of cell-penetrating peptides. **Tier 4 here does not assert that Pinealon is biologically inert — it asserts that the mechanism *as claimed* is implausible and the evidence base is too weak to recommend use.** A genuinely positive result from a well-powered blinded Western RCT in age-related cognitive decline would warrant re-evaluation; that result does not currently exist.
+
+### Discovery and structure
+
+Pinealon is a synthetic **tripeptide** with the sequence:
+
+```
+Glu-Asp-Arg
+ E   D   R
+```
+
+Molecular weight 418.4 Da. The peptide carries one positive charge (Arg side chain, pKa ~12) and two negative charges (Glu γ-carboxyl pKa ~4.3, Asp β-carboxyl pKa ~3.9) at physiological pH — net charge approximately −1. No hydrophobic residues; no cationic clusters; no canonical cell-penetrating-peptide signature.
+
+Pinealon was developed by **Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology** (Институт биорегуляции и геронтологии) in the early-to-mid 2000s, with first published characterisations in the Russian literature around 2007-2008 and the first widely cited English-language Khavinson-group papers around 2010-2012. It belongs to the **"cytogen" subset** of Khavinson peptides — the short synthetic 2-4mers developed as putative active-substance analogues of the older "cytomedine" organ extracts (see §4.2 for the cytomedine vs cytogen distinction).
+
+The "Pinealon" trade name derives from the claimed pineal/CNS bioregulatory activity. The Khavinson-group framing is that Pinealon is the cytogen analogue of the cytomedine **Epithalamin** (a polypeptide extract from bovine pineal gland), in the same way that Epitalon (Ala-Glu-Asp-Gly) is also claimed to be an Epithalamin-derived cytogen. The relationship between Pinealon and Epitalon is therefore conceptually overlapping in the Khavinson framework, with Pinealon framed as more CNS/cortical and Epitalon as more pineal/circadian — though both are claimed to derive from the same parent tissue extract, which immediately raises the question of how two different short peptides extracted from the same source can have distinct organ-specific effects.
+
+### Proposed mechanisms — the Khavinson model
+
+Khavinson and collaborators have published a consistent mechanistic model across roughly two decades, summarised here at face value:
+
+1. **Site-directed DNA binding.** The central claim: Pinealon (and other cytogens) penetrate the cell membrane, traverse the nuclear envelope, and bind directly to promoter regions of specific genes in the major groove of duplex B-DNA. Khavinson 2011 (*Neuro Endocrinol Lett*) and Khavinson 2014 (*Biochemistry Moscow Supplement Series B*) propose this is sequence-specific — i.e., Pinealon's E-D-R sequence "matches" a specific subset of promoter triplets and thereby regulates a specific subset of organ-relevant genes. This model is sometimes called "peptide-DNA bioregulation."
+
+2. **Transcription factor mimicry.** A corollary claim: Pinealon acts as a minimal transcription factor, competing with or mimicking endogenous TF binding to specific promoter elements. The proposed mechanism mirrors classical Brenner-Crick-style coding logic — that a short sequence encodes specific binding information.
+
+3. **Organ-specific gene regulation.** The cytogen programme predicts that each short peptide upregulates a *defined* gene-expression programme tied to a specific organ — Pinealon → CNS/cortical maintenance genes; Epitalon → pineal/melatonin-axis genes; Vesugen → vascular endothelial genes; and so on. This is presented as the explanation for why a small library of short peptides can cover an entire organ-system pharmacopoeia.
+
+4. **Cell-penetrating peptide behaviour.** Implicit in the model is the assumption that Pinealon crosses the plasma membrane unaided by transport machinery, in sufficient quantity to reach intranuclear effective concentrations. Khavinson group papers occasionally reference rhodamine- or fluorescein-labelled cytogen tracking experiments to support this; the labelled-tracer experiments have not been independently reproduced in Western labs at the level of rigour required to distinguish actual cytoplasmic/nuclear localisation from artifacts of fixation, label dissociation, or non-specific surface binding.
+
+5. **Downstream effects** — claimed: upregulation of antioxidant defence (SOD, GPx, catalase), reduction of apoptotic markers (caspase-3, p53 phosphorylation) in stressed neurons, normalisation of neurotransmitter balance (serotonin, dopamine, norepinephrine) in aged rats, improvement of memory and learning in passive-avoidance and Morris water maze paradigms.
+
+### Mechanism critique — the skeptical reading
+
+There are four convergent biophysics objections to the Khavinson cytogen model as it specifically applies to Pinealon. None is fatal in isolation; together they constitute a strong case that the central mechanistic claim is not what is happening, even if some downstream biological effect is real.
+
+**Objection 1: Information theory rules out 3-mer site-specific DNA binding.**
+
+A 3-mer drawn from the 20 proteinogenic amino acids has 20³ = 8,000 possible sequences. The information content of choosing one specific 3-mer is log₂(8,000) ≈ **13 bits**.
+
+A typical transcription-factor binding site in eukaryotic DNA is 6-12 base pairs and must be specified uniquely (or near-uniquely) within a ~3 × 10⁹ bp genome. The information required to locate a single unique site in 3 Gb is log₂(3 × 10⁹) ≈ **31.5 bits**. Real transcription factors achieve specificity using DNA-binding domains of ~50-150 amino acids that contact 6-12 bp through a network of base-specific and phosphate-backbone contacts, with binding free energies of −10 to −15 kcal/mol distributed across multiple residue-base hydrogen bonds, salt bridges, and shape readout. The information capacity of a 150-residue protein domain is more than sufficient to specify 31.5 bits of binding preference; the information capacity of a 3-mer (13 bits) is intrinsically insufficient by a factor of >2× in bits — and worse than that in practice because the available "specificity surface" of a 3-mer is only ~3-5 base-contacting positions at most.
+
+In other words, **a tripeptide cannot, even in principle, bind a unique site in the genome through direct sequence-specific readout** — there are not enough sequence-specifying degrees of freedom in the peptide to discriminate the target site from the ~10⁶-10⁷ alternative sites of similar local geometry that exist by chance in 3 Gb of DNA. Even if Pinealon binds DNA at all, the binding cannot be sequence-directed in the sense the Khavinson model claims. This is the central, and least negotiable, objection.
+
+The standard counter-argument the Khavinson group offers is that the peptide binds with low absolute affinity to many sites simultaneously and exerts an aggregate effect across many promoters. That is a coherent alternative model — but it is not the "site-directed organ-specific gene regulation" model the cytogen literature actually claims, and it does not predict organ-specific effects.
+
+**Objection 2: Serum peptidase kinetics make systemic delivery of intact peptide implausible.**
+
+Free linear peptides in mammalian plasma face an extensive set of degrading enzymes — aminopeptidases (cleaving from the N-terminus), carboxypeptidases (cleaving from the C-terminus), endopeptidases (cleaving internal bonds), and dipeptidyl peptidases (cleaving N-terminal dipeptides). Pinealon's E-D-R sequence has no protection against any of these classes: the N-terminal Glu is a substrate for aminopeptidase A (preferentially cleaves acidic residues); the C-terminal Arg is a high-affinity substrate for carboxypeptidase N (which has strong specificity for basic C-termini and is abundant in plasma); the central E-D bond is a substrate for multiple endopeptidases.
+
+Experimentally measured plasma half-lives of unprotected short peptides typically fall in the range of **1-10 minutes**. Khavinson-group claims of intact systemic delivery after SC, IM, or oral administration have not been confirmed by independent Western pharmacokinetic studies with adequate analytical methods (LC-MS/MS quantification of intact parent peptide vs metabolites). What the rodent labelled-tracer experiments most likely demonstrate is *amino acid* delivery to tissues following peptide hydrolysis — i.e., free Glu, free Asp, and free Arg entering the systemic free amino-acid pool — not delivery of intact tripeptide.
+
+This matters because the entire "organ-specific gene regulation" claim requires the intact tripeptide to reach intranuclear concentrations sufficient for the proposed DNA contact. If only free amino acids reach the tissue, no peptide-specific mechanism can be operating, and any biological effect would be a free-amino-acid effect — which would not be peptide-specific and would be identical across all cytogens with the same amino-acid composition.
+
+**Objection 3: Pinealon lacks the structural motifs required for cell penetration.**
+
+Cell-penetrating peptides (CPPs) are a well-characterised class (TAT 47-57, penetratin, polyarginine R8/R9, MAP, transportan) with shared features: predominantly cationic (multiple Arg or Lys residues — typically 5-9), often amphipathic, often α-helical or capable of forming helical structures upon membrane interaction. The minimum charge density for reliable CPP behaviour is several positive residues clustered in a short window — polyarginine R8 is considered close to the minimum effective oligoarginine.
+
+Pinealon has one Arg, balanced against two acidic residues (Glu, Asp). Net charge is approximately **−1** at physiological pH. There are no hydrophobic residues to enable membrane partitioning. There is no helical propensity in a tripeptide of this composition. **By every established structural criterion for cell penetration, Pinealon should not cross the plasma membrane in any pharmacologically meaningful quantity.** Khavinson-group claims of intracellular and intranuclear localisation conflict with the biophysics literature on what makes a peptide cell-permeable; the conflict is not addressed in the cytogen literature.
+
+**Objection 4: The proposed DNA-binding affinity has not been confirmed by standard biophysics.**
+
+If Pinealon binds B-DNA with the affinity and specificity the Khavinson model requires, that binding should be demonstrable by isothermal titration calorimetry (ITC) measuring binding enthalpy and stoichiometry; by surface plasmon resonance (SPR) measuring on- and off-rates; by X-ray crystallography or cryo-EM of the peptide-DNA complex; or by NMR resolving the peptide chemical-shift perturbation upon DNA binding. These are standard tools that have characterised peptide-DNA interactions for decades for compounds where such interactions are real (e.g., minor-groove binders like distamycin, intercalators like daunorubicin, polyamides). The Khavinson cytogen literature does not contain rigorous biophysics of this kind for Pinealon. The closest published evidence is computational docking and circular dichroism studies, neither of which can confirm specific high-affinity binding.
+
+**Putting the four objections together:** the claim "Pinealon binds specific gene promoters and regulates organ-specific gene expression" requires (a) intact peptide to reach the tissue, (b) intact peptide to enter the cell, (c) intact peptide to enter the nucleus, (d) intact peptide to bind a specific DNA site with sufficient affinity and information content to discriminate that site from background. Each of these four steps is implausible on independent grounds. The conjunction is implausibility-squared.
+
+**What might actually be happening if Pinealon produces real biological effects:**
+- Free amino-acid effects after rapid hydrolysis (most likely null or marginal at the doses used).
+- Transient receptor effects analogous to short neuropeptide signalling (possible in principle but not characterised).
+- Effects from peptide aggregates, contaminants, or formulation excipients in the actual product (a real concern given the sourcing landscape).
+- Placebo and observer-bias effects in unblinded studies (likely contribution to the human evidence).
+- Nonspecific stress-protective effects via free arginine entry into the NO-substrate pool (Arg is a substrate for nitric oxide synthase; downstream free Arg from peptide hydrolysis could have a small NO-related effect).
+
+None of these alternative mechanisms supports the specific organ-targeted gene-regulation narrative.
+
+### Animal evidence
+
+The Khavinson group has published a body of rat studies on Pinealon in cognitive and ischemic injury models. The strongest claims and the weakest methodology elements:
+
+**Strongest claims (rodent):**
+- **Cognitive protection in aged rats.** Khavinson-group studies (Khavinson 2011; Arutjunyan 2010 *Bull Exp Biol Med*) report improvement in passive-avoidance learning, Morris water maze performance, and exploratory behaviour in aged rats treated with Pinealon vs saline controls, with effect sizes commonly reported in the 20-50% range on continuous behavioural endpoints.
+- **Neuroprotection in hypoxia/ischemia models.** Several rat studies report reduced neuronal apoptosis (TUNEL-positive cell count), reduced caspase-3 activation, and preserved hippocampal CA1 cell density after acute hypoxic exposure or middle cerebral artery occlusion when Pinealon is given before or shortly after the insult.
+- **Antioxidant effect.** Reports of increased SOD, catalase, and glutathione activity in cortex and hippocampus of treated rats vs controls.
+- **Prenatal hypoxia model.** Arutjunyan-group studies report developmental protection of rat pups exposed in utero to maternal hypoxia when dams are treated with Pinealon — a model the Khavinson programme has used as a flagship demonstration of cytogen activity.
+
+**Weakest methodology elements:**
+- **Single-lab concentration.** As with the broader cytogen literature, the great majority of positive Pinealon rodent data comes from the St Petersburg Institute or close collaborators. Independent replication outside the network is sparse.
+- **Blinding and randomisation.** Pre-2010 Khavinson-group rodent papers often do not document blinded outcome assessment in the way modern preclinical reporting standards (ARRIVE guidelines, 2010 onwards) require. Behavioural endpoints are particularly vulnerable to observer bias.
+- **Dose-response curves.** Often a single dose is tested vs control rather than a full dose-response, which makes it difficult to distinguish a real pharmacological effect from a noise-floor positive result.
+- **Mechanism of action verification.** The papers proposing antioxidant or anti-apoptotic mechanisms typically measure downstream markers (SOD activity, caspase-3 cleavage) without testing the upstream gene-regulation claim with ChIP-seq, ATAC-seq, or RNA-seq — the modern tools that would test whether Pinealon actually binds promoters and changes transcription as the model predicts.
+- **Positive control absence.** Pinealon is typically compared to saline rather than to an active comparator (e.g., a known neuroprotectant), which makes it impossible to calibrate the effect size against established benchmarks.
+
+### Human evidence — the critical gap
+
+**There are no large Western RCTs of Pinealon.** The human evidence base consists of:
+- A small number of Russian-language publications from the Khavinson institute and collaborating Russian clinical centres, reporting cognitive improvement in elderly subjects with mild cognitive impairment or post-stroke cognitive decline. Sample sizes typically 30-100; blinding inconsistent or absent; outcome measures heterogeneous (MMSE, Russian cognitive batteries); no pre-registration.
+- Inclusion of Pinealon in some Khavinson-group cohort longevity studies (Korkushko 2011; analogous to Epitalon cohort work), which report all-cause mortality differences in elderly Russian cohorts — these have the same methodological issues as the Epitalon cohort work: unblinded administration, non-randomised assignment, healthy-user bias.
+
+**What does not exist:**
+- No Cochrane review of Pinealon.
+- No FDA filings, no EMA filings, no PMDA filings.
+- No registered Phase 2 or 3 trials on ClinicalTrials.gov.
+- No independent Western academic medical centre programme.
+- No publications in high-impact Western neurology, geriatrics, or pharmacology journals.
+
+The contrast with the cognitive-enhancement and neuroprotection literature for established compounds (e.g., the donepezil RCT base, the citicoline stroke trials, the cerebrolysin meta-analyses) is stark: those compounds have multi-thousand-subject blinded randomised trials with pre-specified endpoints. Pinealon does not.
+
+### Bioavailability problem
+
+The tripeptide stability question is the same one that defeats the broader cytogen mechanism: an unprotected linear tripeptide given orally is degraded by gastric pepsin (cleaves at hydrophobic residues — Pinealon has none, providing some protection from pepsin specifically, but not from the general acidic-pH peptide hydrolysis environment), intestinal brush-border peptidases (cleave broadly), and serum aminopeptidase/carboxypeptidase activity within minutes after absorption.
+
+Routes claimed by Khavinson-group and downstream practitioner literature:
+- **Subcutaneous injection** — most common route in the rodent literature and the practitioner peptide subculture. Bypasses GI peptidases but does not protect from plasma peptidases; intact tripeptide half-life in circulation is expected to be minutes.
+- **Intranasal administration** — claimed to bypass blood-brain barrier via olfactory and trigeminal nerve routes. Intranasal delivery of small peptides can achieve some CNS penetration (the route has legitimate pharmacology for oxytocin, insulin, and others), but the fraction of administered dose that actually reaches brain tissue intact is typically <1%. Pinealon-specific intranasal PK has not been rigorously characterised in humans.
+- **Sublingual administration** — claimed to bypass first-pass GI degradation. The buccal mucosa is permeable to small lipophilic molecules; permeability to charged hydrophilic peptides is poor.
+- **Oral administration** — claimed by the Khavinson group to be effective despite the obvious objection that no intact peptide should survive the GI tract. The proposed explanation involves protected uptake by enterocytes via PEPT1 (the di/tripeptide transporter) — PEPT1 does transport tripeptides, so the *uptake* claim is not implausible, but onward systemic delivery of intact peptide vs hydrolysis at the enterocyte basolateral membrane has not been resolved.
+
+**Practical pharmacokinetic bottom line:** none of the proposed routes has been shown to deliver intact Pinealon to CNS target tissue at concentrations sufficient for the proposed DNA-binding mechanism. The most parsimonious reading is that any systemic biological effect observed after administration is mediated by hydrolysis products (free amino acids) or by local effects at the administration site (intranasal trigeminal/olfactory; SC tissue) rather than by intact peptide acting at a CNS receptor or nuclear target.
+
+### Social media framing concern
+
+Pinealon is currently being promoted in the longevity peptide subculture (Twitter/X, biohacker forums, Russian peptide vendors, some podcast circuits) on the basis of claims that substantially exceed the evidence base. Typical framings include "FDA-equivalent approved in Russia" (it is not approved in any pharmacopoeia in the sense Western readers will understand), "telomerase activator" (this claim properly belongs to Epitalon, not Pinealon, and is itself weakly evidenced), "proven to extend lifespan" (no RCT supports this), and "third-generation Khavinson peptide" (a marketing label, not a scientific category).
+
+This document does not dismiss the underlying research question — whether short peptides can produce real biological effects in age-related cognitive decline is an open and legitimate scientific question, and the Khavinson programme has produced a body of work that warrants serious independent evaluation rather than reflexive rejection. The framing concern is specifically about the mismatch between what social media promotion claims for Pinealon (proven, safe, effective, FDA-equivalent) and what the evidence base actually supports (small unblinded trials from a single institutional network; mechanism that is not biophysically plausible as claimed; no Western RCT validation). Apply the same evidence rigour to Pinealon that you would apply to any other compound that arrived via the same channel; the Twitter discourse is not a substitute for that rigour.
+
+### Sourcing concerns
+
+The Pinealon supply chain is dominated by Russian peptide vendors with limited or no third-party quality control. Specific issues:
+
+- **Identity verification.** Independent mass-spec testing of "Pinealon" products is essentially absent in the public literature. Whether the labelled product actually contains Glu-Asp-Arg, contains a different peptide, contains a mixture, or contains free amino acids is not verifiable from the product label or vendor COA alone (vendor COAs are routinely fabricated in the grey-market peptide supply chain).
+- **Batch consistency.** Between-batch variability in peptide content, purity, and impurity profile is high in the Russian peptide market.
+- **Contamination risk.** Endotoxin (LPS) contamination is a routine concern in any non-pharmaceutical-grade peptide intended for injection. LPS at low microgram/dose levels can produce systemic inflammation and is undetectable by visual inspection of the reconstituted solution.
+- **Legal status.** Pinealon is not a controlled substance in most jurisdictions but is also not an approved drug in any Western pharmacopoeia. Sale "for research use only" is the typical legal framing, with possession and personal use in a grey zone that varies by jurisdiction.
+- **Counterfeiting.** Products marketed as Pinealon may be misidentified, mislabelled, contain different cytogens, or be entirely inactive.
+
+### Safety profile
+
+**What is known:**
+- The Khavinson-group rodent toxicology shows no acute toxicity at doses orders of magnitude above the proposed therapeutic range. Free Glu, Asp, and Arg (the hydrolysis products) are normal dietary amino acids with well-characterised safety profiles at the doses delivered.
+- The Khavinson-group human cohort and small-trial data report no serious adverse events. Within the limitations of small unblinded trials, no specific organ toxicity signal has emerged.
+
+**What is not known:**
+- Long-term safety in healthy adults using Pinealon as a continuous "longevity" intervention. The cumulative effect of chronic SC injection of any peptide can include local injection-site reactions, immunogenicity (anti-peptide antibody development), and unknown long-term consequences.
+- Contamination risk from the supply chain — endotoxin exposure, residual synthesis impurities, undisclosed adulterants — is unquantified for any specific product.
+- Interactions with concurrent neurological or psychiatric medication.
+- Effect in individuals with active malignancy. The Khavinson programme's claims of pro-mitotic and pro-regenerative effects, if real, would carry the same theoretical cancer-promotion concern that applies to any growth-promoting peptide, though no specific Pinealon tumour-promotion data exists either way.
+
+### Genotype interactions
+
+Direct genotype interactions are minimal given the uncertain mechanism, but the following are worth noting:
+
+- **APOE ε4 carriers.** Any neuroprotective claim is directly relevant to APOE ε4-associated cognitive decline risk. The challenge is that the evidence supporting a real neuroprotective effect of Pinealon in humans is thin. APOE ε4 carriers who are inclined toward Pinealon for cognitive protection have a better-evidenced alternative stack — mercury/aluminium detoxification (per the dedicated detoxification protocols), B-vitamin methylation support (SUPPLEMENTS.md §1.2), VITACOG-protocol homocysteine reduction, omega-3 from whole fish, mitochondrial support stack (CoQ10, taurine, magnesium, creatine), and seed-oil avoidance. Pinealon does not displace any of those.
+- **DIO2 Thr92Ala het.** Impaired peripheral T4→T3 conversion. The Khavinson model claims pineal/circadian effects from Pinealon; if those effects were real, they could modulate the thyroid-circadian axis. Given the evidence base, this is a theoretical interaction rather than an actionable one.
+- **CLOCK 3111T>C (rs1801260) CC.** Sleep/circadian phase implications. Same caveat as DIO2 — the pineal/circadian claim would be relevant if real, but the underlying evidence does not support clinical recommendation.
+- **MTHFR C677T het / methylation triple-burden.** No direct interaction with Pinealon's proposed mechanism. If the free-amino-acid hypothesis is closer to the truth than the DNA-binding hypothesis, the free Asp and Glu would enter the same amino-acid pool that interacts with one-carbon metabolism, but the contribution from a microgram-dose peptide is trivial relative to dietary protein intake.
+- **9p21.3 CAD risk genotypes.** No specific interaction noted; the cardiovascular safety profile of Pinealon is not characterised.
+
+### Stack interactions
+
+In Khavinson-school adherent protocols, Pinealon is typically stacked with **Epitalon** (the more famous cytogen, claimed pineal/telomerase effects — see §4.2 for methodological framing) and often with one or more additional cytogens (Vesugen, Cortagen) in rotating multi-week cycles. The mechanistic rationale offered is "complementary organ coverage" — Pinealon for cortex, Epitalon for pineal, Vesugen for vasculature, etc.
+
+From a framework standpoint, the stack rationale rests on the same mechanism implausibility as the individual cytogens. Stacking multiple compounds with weak individual evidence does not strengthen the evidence base for any of them. The practical concern with multi-cytogen stacking is amplified exposure to grey-market supply-chain contamination risk — every additional peptide multiplies the endotoxin/impurity exposure surface.
+
+Outside the Khavinson-school circuit, Pinealon is sometimes stacked with Selank or Semax (the other Russian short-peptide CNS programme — see §2.6, §2.7), reflecting the broader Russian neuropeptide research tradition. Selank and Semax have somewhat better mechanism plausibility (Selank is a heptapeptide analogue of tuftsin; Semax is a heptapeptide ACTH 4-10 fragment with established melanocortin/BDNF effects) and are placed in Tier 2 in this document, but the practical sourcing concerns are similar.
+
+### Framework alignment
+
+**Not strongly aligned, not strongly opposed.** The *if-it-works* question on Pinealon — whether a peptide intervention could meaningfully attenuate age-related cognitive decline — is framework-compatible. Pillar 7 (cognitive and neurological reserve) and the broader anti-aging programme would welcome a real cognitive-protective compound if one existed.
+
+The framework concerns are:
+- **Mechanism implausibility as claimed.** The site-directed DNA binding mechanism is not biophysically credible at the tripeptide scale, for the reasons in the critique section.
+- **Evidence quality.** No Western RCT, no independent replication of the strongest claims, no peer-reviewed biophysics of the proposed mechanism.
+- **Supply-chain risk.** Grey-market injectable peptide use carries endotoxin and contamination risk independent of the pharmacology of the active compound.
+- **Opportunity cost.** The interventions with stronger evidence for cognitive protection in framework terms (sleep prioritisation, B-vitamin methylation support, mercury/aluminium detoxification for those with relevant exposure, mitochondrial stack, seed-oil avoidance, regular cardiovascular and resistance exercise, low-dose lithium where indicated) are not displaced by adding Pinealon; they are diluted by it, both in attention and in budget.
+
+**Tier 4 placement holds primarily on evidence-quality and mechanism-plausibility grounds, not on direct framework opposition.** A high-quality Western RCT showing genuine cognitive benefit in a well-defined population would warrant re-evaluation. That trial does not exist.
+
+### Evidence summary table
+
+| Claim | Evidence level | Notes |
+|-------|---------------|-------|
+| Pinealon binds DNA in sequence-specific manner | Weak; mechanism implausible | Information-theoretic ceiling on 3-mer specificity is ~13 bits; ~31.5 bits required to specify unique site in 3 Gb genome. No ITC/SPR/structural confirmation. |
+| Pinealon penetrates the plasma membrane intact | Weak; biophysically implausible | Lacks cationic clusters, hydrophobic motifs, and helical propensity required of CPPs. Khavinson tracer studies not independently replicated by Western methods. |
+| Pinealon survives serum peptidase exposure intact | Weak; pharmacokinetically implausible | Expected plasma half-life of unprotected linear tripeptide is minutes. No LC-MS/MS quantification of intact parent peptide in independent labs. |
+| Pinealon improves cognition in aged rats | Moderate (animal, single-network) | Khavinson group and collaborators report consistent positive findings. Independent Western replication thin. Blinding and dose-response often inadequate. |
+| Pinealon is neuroprotective in rodent hypoxia/ischemia | Moderate (animal, single-network) | Reduced apoptosis markers reported. Mechanism of action not verified with modern tools (ChIP-seq, RNA-seq). |
+| Pinealon increases antioxidant enzyme activity in aged rat brain | Moderate (animal) | Reported downstream marker changes; upstream gene-regulation mechanism not tested. |
+| Pinealon improves cognition in elderly humans | Weak | Small unblinded Russian trials only. No large Western RCTs. No Cochrane review. Not registered on ClinicalTrials.gov. |
+| Pinealon reduces all-cause mortality in elderly humans | Very weak | Khavinson-network cohort studies only; unblinded; non-randomised in the modern sense. Healthy-user and selection bias not controlled. |
+| Pinealon is FDA-approved or equivalent | False | Not approved in any Western pharmacopoeia. Sold as research chemical. |
+| Pinealon is safe acutely in rodents | Strong | No acute toxicity at doses well above proposed therapeutic range. |
+| Pinealon is safe long-term in healthy human adults | Untested | No long-term controlled human safety data. |
+| Pinealon supply chain quality is reliable | Weak / negative | Russian vendor-dominated grey market; independent mass-spec verification absent; endotoxin risk unquantified. |
+
+### Key references
+
+1. Khavinson VK, Solovyov AY, Tarnovskaya SI, Linkova NS (2014) "Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression." *Biochemistry (Moscow) Supplement Series B* 8: 39-49 — foundational cytogen-mechanism paper from originating lab.
+2. Khavinson VK, Malinin VV (2005) *Gerontological Aspects of Genome Peptide Regulation*. Karger, Basel — monograph statement of the peptide-bioregulation framework.
+3. Khavinson VK (2011) "Peptide bioregulation: theory and practice." *Neuro Endocrinol Lett* 32 (Suppl 1): 1-6 — concise mechanistic claims summary.
+4. Arutjunyan A, Kozina L, Stvolinskiy S et al. (2012) "Pinealon protects the rat offspring from prenatal hyperhomocysteinemia." *Int J Clin Exp Med* 5(2): 179-185 — prenatal hypoxia/hyperhomocysteinemia model from Khavinson-collaborating group.
+5. Khavinson VK, Kuznik BI, Tarnovskaya SI, Lin'kova NS (2014) "Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data." *Adv Gerontol* 27(3): 399-406 — Russian-language oriented review.
+6. Korkushko OV, Khavinson VK, Shatilo VB, Antonyuk-Shcheglova IA (2011) "Geroprotective effect of Epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging." *Bull Exp Biol Med* 151(3): 366-369 — Khavinson-network elderly cohort framework (Epitalon parent; relevant context for Pinealon claims).
+7. Sikora E, Bielak-Zmijewska A, Mosieniak G (2016) "Cellular senescence in ageing, age-related disease and longevity" *Curr Vasc Pharmacol* 12(5): 698-706 — broader context for the gerosuppressive claims surrounding the Khavinson programme; written from outside the Khavinson network.
+8. Crick FH (1968) "The origin of the genetic code." *J Mol Biol* 38: 367-379 — classical information-theory framing of sequence specificity that the cytogen DNA-binding model implicitly invokes.
+9. Stormo GD (2000) "DNA binding sites: representation and discovery." *Bioinformatics* 16(1): 16-23 — modern treatment of the information content required to specify transcription factor binding sites in eukaryotic genomes; central to the information-theoretic objection.
+10. Madani F, Lindberg S, Langel Ü, Futaki S, Gräslund A (2011) "Mechanisms of cellular uptake of cell-penetrating peptides." *J Biophys* 2011: 414729 — review of CPP structural requirements; underpins the cell-penetration objection.
+11. Diao L, Meibohm B (2013) "Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides." *Clin Pharmacokinet* 52: 855-868 — review of peptide clearance and stability; underpins the serum peptidase objection.
+12. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) "Synthetic therapeutic peptides: science and market." *Drug Discov Today* 15: 40-56 — overview of why so few short linear peptides become drugs without stabilisation; relevant context.
+13. Brown CM, Smith CA (2009) "The biophysics of transcription factor binding to DNA." *Annu Rev Biophys* 38: 41-58 — biophysics underpinning the affinity-verification objection.
+14. Lindgren M, Hällbrink M, Prochiantz A, Langel Ü (2000) "Cell-penetrating peptides." *Trends Pharmacol Sci* 21: 99-103 — historical CPP review showing the cationic/amphipathic motif requirements.
+15. Lau JL, Dunn MK (2018) "Therapeutic peptides: historical perspectives, current development trends, and future directions." *Bioorg Med Chem* 26: 2700-2707 — modern peptide therapeutics landscape; context for what Western pharma development of a real cognitive peptide would look like, by contrast with the cytogen programme.
+
+### Bottom line
+
+**Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson's St Petersburg group as part of a "cytogen" programme that posits short peptides act as site-directed transcription factor mimetics regulating organ-specific gene expression. The central mechanistic claim is not biophysically credible at the tripeptide scale — a 3-mer carries ~13 bits of sequence information, well below the ~31.5 bits required to specify a unique site in a 3 Gb genome — and is not supported by the standard biophysics of peptide-DNA interaction, peptide cell penetration, or peptide pharmacokinetics. The rodent evidence base is suggestive of some biological effect in cognitive and ischemic models but is concentrated within the originating lab and lacks the independent Western replication, blinded methodology, and mechanism-of-action verification that would establish reliability. The human evidence base is small unblinded Russian trials; there is no Cochrane review, no FDA filing, and no large Western RCT. The supply chain is grey-market with endotoxin and identity verification risks. Tier 4 placement reflects the convergence of mechanism implausibility *as claimed*, evidence-quality failure, and supply-chain risk — not certainty that Pinealon is biologically inert. The legitimate scientific question (do short peptides do anything real for cognitive aging) deserves serious investigation; the current Twitter-promoted product is not a serious vehicle for that investigation.** Higher-leverage cognitive-protection interventions for ε4 carriers and others concerned about cognitive aging include sleep prioritisation, B-vitamin methylation support, mercury and aluminium detoxification where indicated, mitochondrial support stack (CoQ10, taurine, magnesium, creatine), seed-oil avoidance, and regular cardiovascular and resistance exercise — none of which is displaced or improved by adding Pinealon.
+
+---
+
+## 4.4 Semaglutide / Tirzepatide / GLP-1 Receptor Agonists
 
 **Tier:** 4 — Avoid (per existing framework position)
 **Cross-reference:** See SUPPLEMENTS.md Section 4.7 — GLP-1 Receptor Agonists / Semaglutide for the detailed framework critique.
@@ -730,5 +959,5 @@ Detailed analysis: see SUPPLEMENTS.md §4.7.
 - First created: 2026-05-24
 - Scope: therapeutic peptides through the bioenergetic longevity framework lens
 - Sibling document: SUPPLEMENTS.md
-- Status: BPC-157 deep dive complete; all other entries are stubs pending future expansion
-- Framework consistency principle applied: GH/GHRH/GHRP/GHS class placed in Tier 3 not Tier 2 on grounds of chronic IGF-1 → mTOR concern, despite mainstream longevity culture's enthusiasm; mitochondrial peptides (MOTS-c, SS-31, Humanin) and thymosin α-1 placed in Tier 1 as direct framework matches; Khavinson school placed in Tier 4 on evidence-quality grounds; BPC-157 placed in Tier 2 not Tier 1 because of human RCT evidence gap and VEGF/cancer concern.
+- Status: BPC-157 (§2.1) and Pinealon (§4.3) deep dives complete; Khavinson methodological overview (§4.2) expanded; all other entries are stubs pending future expansion
+- Framework consistency principle applied: GH/GHRH/GHRP/GHS class placed in Tier 3 not Tier 2 on grounds of chronic IGF-1 → mTOR concern, despite mainstream longevity culture's enthusiasm; mitochondrial peptides (MOTS-c, SS-31, Humanin) and thymosin α-1 placed in Tier 1 as direct framework matches; Khavinson school placed in Tier 4 on evidence-quality grounds with information-theoretic critique of the 3-mer site-directed DNA binding mechanism articulated in the Pinealon deep dive; BPC-157 placed in Tier 2 not Tier 1 because of human RCT evidence gap and VEGF/cancer concern.